Savient Pharmaceuticals (SVNT -9%) takes a hit after its Q4 beat expectations on a per share...

|About: Savient Pharmaceuticals, Inc. (SVNTQ)|By:, SA News Editor

Savient Pharmaceuticals (SVNT -9%) takes a hit after its Q4 beat expectations on a per share basis, but came up far short on revenue as net sales of Krystexxa posted a marginal 3% increase over Q3. Bottom line margins were also impacted by a cost of goods charge to Krystexxa inventory that the company doesn't believe will be sold prior to expiration.